Forte Biosciences (FBRX) S-4/A Registration of securities issued in business combination transactions (amended)

Exhibit 10.18

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT HAS BEEN OMITTED

BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF

PUBLICLY DISCLOSED. INFORMATION THAT HAS BEEN OMITTED HAS BEEN NOTED IN THIS

DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK “[***]”.

PUBLIC HEALTH SERVICE

PATENT LICENSE AGREEMENT —EXCLUSIVE

ThisAgreement is based on the model Patent License Exclusive Agreement adopted by the U.S. Public Health Service(“PHS”) Technology Transfer Policy Board for use by components of the National Institutes of Health(“NIB”), the Centers for Disease Control and Prevention(“CDC”), and the Food and Drug Administration(“FDA”), which are agencies of the PHS within the Department of Health and Human Services(“HHS”).

This Cover Page identifies the Parties to thisAgreement:

The U.S. Department of Health and Human Services, as represented by

National Institute of Allergy and Infectious Diseases

an Institute or Center (hereinafter referred to as the“IC”) of the

National Institutes of Health

and

Forte Biosciences Inc.

hereinafter referred to as the“Licensee”,

created and operating under the laws of Delaware

Tax ID No.: [***]

A-429-2017

CONFIDENTIAL

NIH Patent License Agreement-Exclusive

Model 10-2015 Page 1 of 36 [Final] [Forte Biosciences]

[***] Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

For theIC internal use only:

LicenseNumber:                             L-018-2018

License ApplicationNumber:        A-429-2017

Serial Number(s) of Licensed Patent(s) or Patent Application(s):

1.    US Provisional Application 62/324,762

2.    PCT/US2017/028133

Cooperative Research and Development Agreement (CRADA) Number (if a subject invention): None

Additional Remarks: None

Public Benefits(s): The public will benefit from the development of a new therapeutic to treat atopic dermatitis, a chronic inflammatory skin disease that is a cause of considerable economic and social burden. Atopic dermatitis affects ~25% of children in developed and developing countries, so there is a significant population that needs new and effective therapies.

This Patent License Agreement, hereinafter referred to as the“Agreement”,consists of this Cover Page, an attachedAgreement,a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D (Benchmarks and Performance), Appendix E (Commercial Development Plan), Appendix F (Example Royalty Report), and Appendix G (Royalty Payment Options).

A-429-2017

CONFIDENTIAL

NIH Patent License Agreement-Exclusive

Model 10-2015 Page 2 of 36 [Final] [Forte Biosciences]

[***] Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

TheICand theLicensee agree as follows:

1. BACKGROUND

1.1 In the course of conducting biomedical and behavioral research, theICinvestigatorsmade inventions that may have commercial applicability.

1.2 By assignment of rights fromICemployees and other inventors,HHS,on behalf of theGovernment,owns intellectual property rights claimed in any United States or foreign patent applications or patents corresponding to the assignedinventions. HHSalso ownsany tangible embodiments of these inventions actually reduced to practice by theIC.

1.3 The Secretary of HHS has delegated to the IC the authority to enter into this Agreement for the licensing of rights to these inventions.

1.4 TheICdesires to transfer these inventions to the private sector through commercialization licenses to facilitate the commercial development of products and processes for public use and benefit.

1.5 TheLicenseedesires to acquire commercialization rights to certain of these inventions in order to develop processes, methods, or marketable products for public use and benefit.

2. DEFINITIONS

2.1 “Affiliate(s)”means a corporation or other business entity, which directly or indirectly is controlled by or controls, or is under common control with theLicensee. For this purpose, the term “control” shall mean ownership of more than fiftypercent (50%) of the voting stock or other ownership interest of the corporation or other business entity, or the power to elect or appoint more than fifty percent (50%) of the members of the governing body of the corporation or other business entity.

2.2 “Benchmarks”mean the performance milestones that are set forth in Appendix D.

2.3 “Commercial Development Plan” means the written commercialization plan attached as Appendix E.

2.4 “CRADA”means a Cooperative Research and Development Agreement.

2.5 “Fair Value” means the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date; for the calculation of assignment royalty, the measurement date forFair Valueshall be the date when all parties to the assignment have signed the assignment of thisAgreementper Paragraph 14.7 ofthisAgreement.

2.6 “FDA” meansthe Food and Drug Administration.

A-429-2017

CONFIDENTIAL

NIH Patent License Agreement-Exclusive

Model 10-2015 Page 3 of 36 [Final] [Forte Biosciences]

[***] Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

2.7 “First Commercial Sale”means the initial transfer by or on behalf of theLicenseeor itssublicensees of the Licensed Productsor the initial practice of a Licensed Processby or on behalf of theLicensee or its sublicensees in exchange for cash or some equivalent to which value can be assigned for the purpose of determiningNet Sales.

2.8 “Government”means the Government of the United States of America.

2.9 “Licensed Fields of Use”means the fields of use identified in Appendix B.

2.10 “Licensed Patent Rights” shall mean:

(a) Patent applications (including provisional patent applications and PCT patent applications) or patents listed in Appendix A, all divisions and continuations of these applications, all patents issuing from these applications, divisions, and continuations, and any reissues, reexaminations, and extensions of these patents;

(b) to the extent that the following contain one or more claims directed to the invention or inventions disclosed in 2.9(a):

(i) continuations-in-part of 2.9(a);

(ii) all divisions and continuations of thesecontinuations-in-part;

(iii) all patents issuing from thesecontinuations-in-part, divisions, and continuations;

(iv) priority patent application(s) of 2.9(a); and

(v) any reissues, reexaminations, and extensions of these patents;

(c) to the extent that the following contain one or more claims directed to the invention or inventions disclosed in 2.9(a): all counterpart foreign and U.S. patent applications and patents to 2.9(a) and 2.9(b), including those listed in Appendix A; and

(d) Licensed Patent Rightsshallnotinclude 2.9(b) or 2.9(c) to the extent that they contain one or more claims directed to new matter which is not the subject matter disclosed in 2.9(a).

2.11 “Licensed Processes”means processes which, in the course of being practiced, would be within the scope of one or more claims of theLicensed Patent Rightsthat have not been held unpatentable, invalid or unenforceable by an unappealed or unappealable judgment of a court of competent jurisdiction.

2.12 “Licensed Products”means tangible materials which, in the course of manufacture, use, sale, or importation, would be within the scope of one or more claims of theLicensed Patent Rightsthat have not been held unpatentable, invalid or unenforceable by an unappealed or unappealable judgment of a court of competent jurisdiction.

A-429-2017

CONFIDENTIAL

NIH Patent License Agreement-Exclusive

Model 10-2015 Page 4 of 36 [Final] [Forte Biosciences]

[***] Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

2.13 “Licensed Territory”means the geographical area identified in Appendix B.

2.14 “Net Sales” means the total gross receipts for sales ofLicensed Productsor practice ofLicensed Processesby or on behalf ofthe Licenseeor its sublicensees,and from leasing,renting, or otherwise making theLicensed Productsavailable to others without sale or other dispositions, whether invoiced or not, less returns and allowances, packing costs, insurance costs, freight out, taxes or excise duties imposed on the transaction (if separately invoiced), and wholesaler and cash discounts in amounts customary in the trade to the extent actually granted. No deductions shall be made for commissions paid to individuals, whether they are with independent sales agencies or regularly employed by theLicensee, or sublicensees, and on its payroll, or for the cost of collections.

2.15 “Practical Application”means to manufacture inthe case of a composition or product, to practice in the case of a process or method, or to operate in the case of a machine or system; and in each case, under these conditions as to establish that the invention is being utilized and that its benefitsare to the extent permitted by law orGovernment regulations available to the public on reasonable terms.

2.16 “Research License”means a nontransferable, nonexclusive license tomake and to use the Licensed Productsor theLicensed Processes as defined by theLicensed Patent Rightsfor purposes of research and not for purposes of commercial manufacture or distribution or in lieu of purchase.

3. GRANT OF RIGHTS

3.1 TheIC hereby grants and the Licensee accepts, subject to the terms and conditions of thisAgreement,an exclusive license under the Licensed Patent Rightsin the Licensed Territoryto make and have made, to use and have used, to sell and have sold, to offer to sell, and to import anyLicensed Productsin the Licensed Fields of Useand to practice and have practiced anyLicensed Process(es)in the Licensed Fields of Use.

3.2 This Agreementconfers no license or rights by implication, estoppel, or otherwise under any patent applications or patents of theIC other than theLicensed Patent Rightsregardless of whether these patents are dominant or subordinate to the Licensed Patent Rights.

4. SUBLICENSING

4.1 Upon written approval, which shall include prior review of any sublicense agreement by the ICand which shall not be unreasonably withheld, the Licensee may enter into sublicensing agreements under the Licensed Patent Rights.

4.2 The Licenseeagrees that any sublicenses granted by it shall provide that the obligations to the ICof Paragraphs5.1-5.4, 8.1, 10.1, 10.2, 12.5, and13.8-1310 of thisAgreementshall be binding upon the sublicensee as if it were a party to this Agreement.The Licensee further agrees to attach copies of these Paragraphs to all sublicense agreements.

A-429-2017

CONFIDENTIAL

NIH Patent License Agreement-Exclusive

Model 10-2015 Page 5 of 36 [Final] [Forte Biosciences]

[***] Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

4.3 Any sublicenses granted by theLicensee shall provide for the termination of the sublicense, or the conversion to a license directly between the sublicensees and theIC,at the option of the sublicensee, upon termination of this Agreement under Article 13. This conversion is subject to theICapproval and contingent upon acceptance by the sublicensee of the remaining provisions of this Agreement.

4.4 TheLicensee agrees to forward to theIC a complete copy of each fully executed sublicense agreement postmarked within thirty (30) days of the execution of the agreement. To the extent permitted by law, theICagrees to maintain each sublicense agreement in confidence.

5. STATUTORY AND NIH REQUIREMENTS AND RESERVED GOVERNMENT RIGHTS

5.1       (a) theIC reserves on behalf of theGovernment an irrevocable, nonexclusive, nontransferable, royalty-free license for the practice of all inventions licensed under theLicensed Patent Rights throughout the world by or on behalf of theGovernment and on behalf of any foreign government or international organization pursuant to any existing or future treaty or agreement to which theGovernment is a signatory. Prior to theFirst Commercial Sale,the Licenseeagrees to provide the IC with reasonable quantities of the Licensed Products or materials made through theLicensed Processes forICresearch use; and

(b) in the event that theLicensedPatent Rightsare Subject Inventions made underCRADA, theLicensee grants to theGovernment, pursuant to15 U.S.C. 3710a(b)( I )(A), a nonexclusive, nontransferable, irrevocable,paid-up license to practice theLicensed Patent Rights or have theLicensed PatentRights practiced throughout the world by or on behalf of theGovernment. In the exercise of this license, theGovernment shall not publicly disclose trade secrets or commercial or financial information that is privileged or confidential within the meaning of5 U.S.C. 552(b)(4) or which would be considered as such if it had been obtained from anon-Federal party. Prior to theFirstCommercial Sale, the Licensee agrees to provide theICwith reasonable quantities of theLicensed Products or materials made through theLicensed Processes forIC research use.

5.2 The Licensee agrees that products used or sold in the United States embodying the Licensed Products or produced through use of the Licensed Processes shall be manufactured substantially in the United States, unless a written waiver is obtained in advance from the IC.

5.3 TheLicensee acknowledges that the IC may enter into futureCRADAsunder theFederal Technology Transfer Act of 1986 that relate to the subject matter of thisAgreement. TheLicensee agrees not to unreasonably deny requests for aResearch License from future collaborators with theICwhen acquiring these rights is necessary in order to make aCRADAproject feasible. TheLicensee may request an opportunity to join as a party to the proposedCRADA.

5.4       (a) in addition to the reserved license of Paragraph 5.1, theICreserves the right to grantResearch Licenses directly or to require theLicensee to grantResearchLicenses on

A-429-2017

CONFIDENTIAL

NIH Patent License Agreement-Exclusive

Model 10-2015 Page 6 of 36 [Final] [Forte Biosciences]

[***] Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

reasonable terms. The purpose of theseResearch Licenses is to encourage basic research, whether conducted at an academic or corporate facility. In order to safeguard theLicensed Patent Rights, however, theIC shall consult with theLicensee before granting to commercial entities aResearch License or providing to them research samples of materials made through theLicensed Processes ; and

(b) in exceptional circumstances, and in the event that theLicensed Patent Rightsare Subject Inventions made under aCRADA, theGovernment,pursuantto 15U.S.C. 3710a(b)( l)(B). retains the right to require the Licensee to grant to a responsible applicant a nonexclusive, partially exclusive, or exclusive sublicense to usetheLicensed Patent Rightsin the Licensed Field of Useon terms that are reasonable under the circumstances, or if the Licenseefails to grant thislicense, the Governmentretains the right to grant the license itself. Theexercise ofthese rights by theGovernmentshall only be in exceptional circumstances and onlyif the Governmentdetermines:

(i) the action is necessary to meet health or safety needs that are not reasonably satisfied by the Licensee;

(ii) the action is necessary to meet requirements for public use specified by Federal regulations, and these requirements are not reasonably satisfied by the Licensee;or

(iii) the Licenseehas failed to comply with an agreement containing provisions described in15 U.S.C. 10a(c)(4)(B);and

(c) the determination made by theGovernmentunder this Paragraph 5.4 is subject to administrative appeal and judicialreview under35 U.S.C. &203(b).

6. ROYALTIES AND REIMBURSEMENT

6.1 The Licenseeagrees to pay the ICa noncreditable, nonrefundable license issue royalty as set forth in Appendix C.

6.2 The Licenseeagrees to pay theIC a nonrefundable minimum annual royalty as set forth in Appendix C.

6.3 The Licenseeagrees to pay the ICearned royalties as set forth in Appendix C.

6.4 The Licenseeagrees to pay the ICbenchmark royalties as set forth in Appendix C.

6.5 The Licenseeagrees to pay theICsublicensing royalties as set forth in Appendix C.

6.6 A patent or patent application licensed under this Agreementshall cease to fall within the Licensed Patent Rightsfor the purpose of computing earned royalty payments in any given country on the earliest of the dates that:

A-429-2017

CONFIDENTIAL

NIH Patent License Agreement-Exclusive

Model 10-2015 Page 7 of 36 [Final] [Forte Biosciences]

[***] Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

(a) the application has been abandoned and not continued;

(b) the patent expires or irrevocably lapses, or

(c) the patent has been held to be invalid or unenforceable by an unappealed or unappealable decision of a court of competent jurisdiction or administrative agency.

6.7 No multiple royalties shall be payable because anyLicensed ProductsorLicensed Processesare covered by more than one of the Licensed Patent Rights.

6.8 On sales of theLicensed Productsby the Licenseeto sublicensees or on sales made in other than an arms-length transaction, the value of theNet Salesattributed under this Article 6 to this transaction shall be that which would have been received in an arms-length transaction, based on sales of like quantity and quality products on or about the time of this transaction.

6.9 With regard to unreimbursed expenses associated with the preparation, filing, prosecution, and maintenance of all patent applications and patents included within the Licensed Patent Rightsand paid by the ICprior to the effective date of thisAgreement,the Licenseeshall pay theIC,as an additional royalty, within sixty (60) days of theIC’ssubmission of a statement and request for payment to theLicensee,an amount equivalent to these unreimbursed expenses previously paid by the IC.

6.10 With regard to unreimbursed expenses associated with the preparation, filing, prosecution, and maintenance of all patent applications and patents included within theLicensed Patent Rightsand paid by the ICon or after the effective date of thisAgreement,theIC,at its sole option, may require the Licensee:

(a) to pay the ICon an annual basis, within sixty (60) days of the IC’ssubmission of a statement and request for payment, a royalty amount equivalent to these unreimbursed expenses paid during the previous calendar year(s);

(b) to pay these unreimbursed expenses directly to the law firm employed by the ICto handle these functions. However, in this event, theICand not the Licenseeshall be the client of the law firm; or

(c) in limited circumstances, the Licenseemay be given the right toassumeresponsibility for the preparation, filing, prosecution, or maintenance of any patent application or patent included with theLicensed Patent Rights.In that event, theLicenseeshall directly pay the attorneys or agents engaged to prepare, file, prosecute, or maintain these patent applications or patents and shall provide theICwith copies of each invoice associated with these services as well as documentation that these invoices have been paid.

6.11 The ICagrees, upon written request, to provide the Licenseewith summaries of patent prosecution invoices for which theIChas requested payment from theLicenseeunder Paragraphs 6.9 and6.10. TheLicenseeagrees that all information provided by theICrelated to patent prosecution costs shall be treated as confidential commercial information and shall not be released to a third party except as required by law or a court of competent jurisdiction.

A-429-2017

CONFIDENTIAL

NIH Patent License Agreement-Exclusive

Model 10-2015 Page 8 of 36 [Final] [Forte Biosciences]

[***] Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

6.12 The Licenseemay elect to surrender its rights in any country of the Licensed Territoryunder any of theLicensed Patent Rightsupon ninety (90) days written notice to theICand owe no payment obligation under Paragraph 6.10 for patent-related expenses paid in that country after ninety (90) days of the effective date of the written notice.

7. PATENT FILING, PROSECUTION, AND MAINTENANCE

7.1 Except as otherwise provided in this Article 7, the ICagrees to take responsibility for, but to consult with, the Licensee in the preparation, filing, prosecution, and maintenance of any and all patent applications or patents included inthe Licensed Patent Rightsand shall furnish copies of relevant patent-related documents to theLicensee.

7.2 Upon the IC’s written request, the Licensee shall assume the responsibility for the preparation, filing, prosecution, and maintenanceofany and all patent applications or patents included in theLicensed Patent Rightsandshall, on an ongoing basis, promptly furnish copies of all patent-related documents to the IC.In this event, the Licenseeshall, subject to the prior approval of the IC, select registered patent attorneys or patent agents to provide these services on behalf of the Licenseeand the IC.The ICshallprovide appropriatepowersof attorney and other documents necessary to undertake this action to the patent attorneys or patent agents providing these services. The Licenseeand its attorneys or agents shallconsult with the ICin all aspects of the preparation, filing, prosecution and maintenance of patent applications and patents included within theLicensed Patent Rightsand shall provide the ICsufficient opportunity to comment on any document that the Licensee intends to file or to cause to be filed with the relevant intellectual property or patent office.

7.3 At any time, theIC may provide theLicensee with written notice that theIC wishes to assume control of the preparation, filing, prosecution, and maintenance of any and all patent applications or patents included in theLicensed Patent Rights. If theIC elects to reassume these responsibilities, theLicensee agrees to cooperate fully with theIC, its attorneys, and agents in the preparation, filing, prosecution, and maintenance of any and all patent applications or patents included in theLicensed Patent Rights and to provide theIC with complete copies of any and all documents or other materials that theIC deems necessary to undertake such responsibilities. TheLicensee shall be responsible for all costs associated with transferring patent prosecution responsibilities to an attorney or agent of theIC’s choice.

7.4 Each party shall promptly inform the other as to all matters that come to its attention that may affect the preparation, filing, prosecution, or maintenance of theLicensed Patent Rights and permit each other to provide comments and suggestions with respect to the preparation, filing, prosecution, and maintenance of theLicensed Patent Rights, which comments and suggestions shall be considered by the other party.

A-429-2017

CONFIDENTIAL

NIH Patent License Agreement-Exclusive

Model 10-2015 Page 9 of 36 [Final] [Forte Biosciences]

[***] Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

8. RECORD KEEPING

8.1 TheLicensee agrees to keep accurate and correct records of theLicensed Products made, used, sold, or imported and theLicensed Processes practiced under thisAgreement appropriate to determine the amount of royalties due theIC. These records shall be retained for at least five (5) years following a given reporting period and shall be available during normal business hours for inspection, at the expense of theIC, by an accountant or other designated auditor selected by theIC for the sole purpose of verifying reports and royalty payments hereunder. The accountant or auditor shall only disclose to theIC information relating to the accuracy of reports and royalty payments made under this Agreement. If an inspection shows an underreporting or underpayment in excess of five percent (5%) for any twelve (12) month period, then theLicenseeshall reimburse theIC for the cost of the inspection at the time the Licensee pays the unreported royalties, including any additional royalties as required by Paragraph 9.8. All royalty payments required under this Paragraph shall be due within sixty (60) days of the date theIC provides to theLicensee notice of the payment due.

9. REPORTS ON PROGRESS. BENCHMARKS, SALES, AND PAYMENTS

9.1 Prior to signing thisAgreement, theLicensee has provided theIC with theCommercial Development Plan in Appendix E, under which theLicensee intends to bring the subject matter of theLicensed Patent Rights to the point ofPractical Application. ThisCommercialDevelopment Plan is hereby incorporated by reference into this Agreement. Based on this plan, performanceBenchmarks are determined as specified in Appendix D.

9.2 TheLicensee shall provide written annual reports on its product development progress or efforts to commercialize underthe Commercial Development Plan for each of the Licensed Fields of Usewithin sixty (60) days after December 31 of each calendar year. These progress reports shall include, but not be limited to: progress on research and development, status of applications for regulatory approvals, manufacture and status of sublicensing, marketing, importing, and sales during the preceding calendar year, as well as, plans for the present calendar year. The IC also encourages these reports to include information on any of the Licensee’s public service activities that relate to the Licensed Patent Rights. If reported progress differs from that projected in theCommercial Development PlanandBenchmarks,theLicensee shall explain the reasons for these differences. In the annual report, theLicensee may propose amendments to theCommercialDevelopmentPlan,acceptance of which by theIC may not be denied unreasonably. TheLicensee agrees to provide any additional information reasonably required by theIC to evaluate theLicensee’s performance under thisAgreement.TheLicenseemay amend theBenchmarks at any time upon written approval by theIC. TheIC shall not unreasonably withhold approval of any request of theLicenseeto extend the time periods of this schedule if the request is supported by a reasonable showing by the Licensee of diligence in its performance under theCommercial Development Plan andtoward bringing theLicensed Productsto the point ofPractical Applicationasdefined in37 C.F.R.§404.3(d). TheLicensee shall amend theCommercial DevelopmentPlanandBenchmarksat the request of theIC to address anyLicensedFields of Use not specifically addressed in the plan originally submitted.

A-429-2017

CONFIDENTIAL

NIH Patent License Agreement-Exclusive

Model 10-2015 Page 10 of 36 [Final] [Forte Biosciences]

[***] Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

9.3 TheLicensee shall report to theICthe dates for achievingBenchmarksspecified in Appendix D and theFirst Commercial Salein each country in theLicensed Territorywithin thirty (30) days of such occurrences.

9.4 TheLicensee shall submit to theIC,within sixty (60) days after each calendar half-year ending June 30 and December 31, a royalty report, as described in the example in Appendix F, setting forth for the preceding half-year period the amount of theLicensed Productssold orLicensed Processes practiced by or on behalf of theLicensee in each country within theLicensed Territory, theNet Sales, and the amount of royalty accordingly due. With each royalty report, theLicensee shall submit payment of earned royalties due. If no earned royalties are due to the IC for any reporting period, the written report shall so state. The royalty report shall be certified as correct by an authorized officer of theLicensee and shall include a detailed listing of all deductions made under Paragraph 2.13 to determineNet Salesmadeunder Article 6 to determine royalties due. The royalty report shall also identify the site of manufacture for theLicensedProduct(s)sold in the United States.

9.5 TheLicensee agrees to forward semi-annually to theICa copy of these reports received by theLicensee from its sublicensees during the preceding half-year period as shall be pertinent to a royalty accounting to theIC by theLicensee for activities under the sublicense.

9.6 Royalties due under Article 6 shall be paid in U.S. dollars and payment options are listed in Appendix G. For conversion of foreign currency to U.S. dollars, the conversion rate shall be the New York foreign exchange rate quoted inThe Wall Street Journalon the day that the payment is due. Any loss of exchange, value, taxes, or other expenses incurred in the transfer or conversion to U.S. dollars shall be paid entirely by theLicensee. The royalty report required by Paragraph 9.4 shall be mailed to theIC at its address forAgreementNotices indicated on the Signature Page.

9.7 TheLicensee shall be solely responsible for determining if any tax on royalty income is owed outside the United States and shall pay the tax and be responsible for all filings with appropriate agencies of foreign governments.

9.8 Additional royalties may be assessed by theIC onany payment that is more than ninety (90) days overdue at the rate of one percent (1%) per month. This one percent(1%)per month rate may be applied retroactively from the original due date until the date of receipt by theICof the overdue payment and additional royalties. The payment of any additional royalties shall not prevent theICfromexercising any other rights it may have as a consequence of the lateness of any payment.

9.9 All plans and reports required by this Article 9 and marked “confidential” by theLicensee shall, to the extent permitted by law, be treated by theICas commercial and financial information obtained from a person and as privileged and confidential, and any proposed disclosure of these records by theICunder the Freedom of Information Act (FOIA),5 U.S.C.§552 shall be subject to the predisclosure notification requirements of45 C.F.R.§5.65(d).

A-429-2017

CONFIDENTIAL

NIH Patent License Agreement-Exclusive

Model 10-2015 Page 11 of 36 [Final] [Forte Biosciences]

[***] Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

10. PERFORMANCE

10.1 TheLicensee shall use its reasonable commercial efforts to bring theLicensed Productsand the Licensed ProcessestoPractical Application.“Reasonable commercial efforts” for the purposes of this provision shall include adherence to theCommercial Development Planin Appendix E and performance of theBenchmarksinAppendix D. The efforts of a sublicensee shall be considered the efforts of theLicensee.

10.2 Upon the First CommercialSale, until the expiration or termination of thisAgreement,theLicenseeshall use its reasonable commercial efforts to make theLicensed Products and theLicensed Processesreasonably accessible to the United States public.

10.3 TheLicensee agrees, after itsFirst Commercial Sale, to make reasonable quantities of theLicensed Products or materials produced through the use of theLicensed Processes available to patient assistance programs.

10.4 TheLicensee agrees, after itsFirst Commercial Saleand as part of its marketing and product promotion, to develop educational materials (e.g., brochures, website, etc.) directed to patients and physicians detailing the Licensed Productsor medicalaspects of the prophylactic and therapeutic uses of theLicensed Products.

10.5 TheLicensee agrees to supply, to the Mailing Address forAgreementNotices indicated on the SignaturePage, the Office of Technology Transfer,NIHwith inert samples of theLicensedProductsor the Licensed Processesor their packaging for educational and display purposes only.

11. INFRINGEMENT AND PATENT ENFORCEMENT

11.1 TheICandtheLicensee agree to notify each other promptly of each infringement or possible infringement of theLicensed Patent Rights,as well as, any facts which may affect the validity,scope, or enforceability of theLicensed Patent Rightsof which either party becomes aware.

11.2 Pursuant to thisAgreement and the provisions of35 U.S.C. Chapter 29, the Licensee may:

(a) bring suit in its own name, at its own expense, and on its own behalf for infringement of presumably valid claims in theLicensed Patent Rights;

(b) in any suit, enjoin infringement and collect for its use, damages, profits, and awards of whatever nature recoverable for the infringement; or

(c) settle any claim or suit for infringement of theLicensed Patent Rights provided, however, that theIC and appropriateGovernment authorities shall have the first right to take such actions; and

(d) if theLicensee desires to initiate a suit for patent infringement, theLicensee shall notify theIC in writing. If theIC does not notify theLicensee of its intent to pursue legal action within ninety (90) days, theLicensee shall be free to initiate suit. TheIC shall have a continuing right to intervene in the suit. TheLicenseeshall take no

A-429-2017

CONFIDENTIAL

NIH Patent License Agreement-Exclusive

Model 10-2015 Page 12 of 36 [Final] [Forte Biosciences]

[***] Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

action to compel the Governmenteither to initiate or to join in anysuit for patent infringement. TheLicensee may request theGovernmentto initiate or join in any suitif necessary to avoid dismissal of thesuit. Should the Governmentbe made a party to anysuit, theLicenseeshall reimburse the Governmentfor any costs, expenses, or fees which the Governmentincurs as a result of the motion or other action, including all costs incurred by theGovernment in opposingthe motion or other action. In all cases, theLicensee agrees to keep theICreasonably apprised of the status and progress of any litigation. Before the Licenseecommences an infringement action, theLicensee shall notify theICand give careful consideration to the views of theIC and to any potential effects of the litigation on the public health in deciding whether to bring suit.

11.3 In the event that a declaratory judgment action alleging invalidity ornon-infringement of any of theLicensed Patent Rightsshall be brought against the Licenseeor raised by way of counterclaim or affirmative defense in an infringement suit brought by theLicensee under Paragraph 11.2, pursuant to thisAgreementand the provisions of35 U.S.C. Chanter 29 or other statutes, theLicenseemay:

(a) defend the suit in its own name, at its own expense, and on its own behalf for presumably valid claims in theLicensed Patent Rights;

(b) in any suit, ultimately to enjoin infringement and to collect for its use, damages, profits, and awards of whatever nature recoverable for the infringement; and

(c) settle any claim or suit for declaratory judgment involving theLicensed Patent Rights-provided, however, that theICand appropriate Government authorities shall have the first right to take these actions and shall have a continuing right to intervene in the suit; and

(d) if theIC does not notify theLicensee of its intent to respond to the legal action within a reasonable time, theLicensee shall be free to do so. TheLicensee shall take no action to compel theGovernment either to initiate or to join in any declaratory judgment action. TheLicensee may request theGovernment to initiate or to join any suit if necessary to avoid dismissal of the suit. Should theGovernment be made a party to any suit by motion or any other action of theLicensee, theLicensee shall reimburse theGovernment for any costs, expenses, or fees, which theGovernment incurs as a result of the motion or other action. If theLicensee elects not to defend against the declaratory judgment action, theIC, at its option, may do so at its own expense. In all cases, theLicensee agrees to keep theIC reasonably apprised of the status and progress of any litigation. Before theLicensee commences an infringement action, theLicensee shall notify theIC and give careful consideration to the views of theIC and to any potential effects of the litigation on the public health in deciding whether to bring suit.

11.4 In any action under Paragraphs 11.2 or 11.3 the expenses including costs, fees, attorney fees, and disbursements, shall be paid by theLicensee. The value of any recovery made by theLicensee through court judgment or settlement shall be treated asNet Sales and subject to earned royalties.

A-429-2017

CONFIDENTIAL

NIH Patent License Agreement-Exclusive

Model 10-2015 Page 13 of 36 [Final] [Forte Biosciences]

[***] Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

11.5 TheIC shall cooperate fully with theLicensee in connection with any action under Paragraphs 11.2 or 11.3. TheIC agrees promptly to provide access to all necessary documents and to render reasonable assistance in response to a request by theLicensee.

12. NEGATION OF WARRANTIES AND INDEMNIFICATION

12.1 TheIC offers no warranties other than those specified in Article 1.

12.2 TheIC does not warrant the validity of theLicensed Patent Rights and makes no representations whatsoever with regard to the scope of theLicensed Patent Rights, or that theLicensed Patent Rights may be exploited without infringing other patents or other intellectual property rights of third parties.

12.3 THEIC MAKES NO WARRANTIES, EXPRESS OR IMPLIED, OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF ANY SUBJECT MATTER DEFINED BY THE CLAIMS OF THELICENSED PATENT RIGHTS OR TANGIBLE MATERIALS RELATED THERETO.

12.4 TheIC does not represent that it shall commence legal actions against third parties infringing theLicensed Patent Rights.

12.5 TheLicensee shall indemnify and hold theIC, its employees, students, fellows, agents, and consultants harmless from and against all liability, demands, damages, expenses, and losses, including but not limited to death, personal injury, illness, or property damage in connection with or arising out of

(a) the use by or on behalf of theLicensee, its sublicensees, directors, employees, or third parties of anyLicensed Patent Rights; or

(b) the design, manufacture, distribution, or use of anyLicensed Products,Licensed Processes or materials by theLicensee, or other products or processes developed in connection with or arising out of theLicensed Patent Rights.

12.6 TheLicenseeagrees to maintain a liability insurance program consistent with sound business practice.

13. TERM, TERMINATION, AND MODIFICATION OF RIGHTS

13.1 ThisAgreement iseffective when signed by all parties, unless the provisions of Paragraph 14.16 are not fulfilled, and shall extend to the expiration of the last to expire of theLicensed Patent Rightsunless sooner terminated as provided in this Article 13.

13.2 In the event that the Licensee is in default in the performance of any material obligations under thisAgreement, including but not limited to the obligations listed in Paragraph 13.5,

A-429-2017

CONFIDENTIAL

NIH Patent License Agreement-Exclusive

Model 10-2015 Page 14 of 36 [Final] [Forte Biosciences]

[***] Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

and if the default has not been remedied within ninety (90) days after the date of notice in writing of the default, theIC may terminate thisAgreement by written notice and pursue outstanding royalties owed through procedures provided by theFederal Debt Collection Act.

13.3 In the event that theLicenseebecomes insolvent, files a petition in bankruptcy, has such a petitionfiled against it, determines to file a petition in bankruptcy, or receives notice of a third party’s intention to file an involuntary petition in bankruptcy, theLicensee shall immediately notify theICin writing.

13.4 TheLicensee shall have a unilateral right to terminate thisAgreement or any licenses in any country or territory by giving theIC sixty (60) days written notice to that effect.

13.5 TheICshall specifically have the right to terminate or modify, at its option, thisAgreement,if theICdetermines that theLicensee:

(a) is not executing theCommercial Development Plansubmitted with its request for a license and theLicensee cannot otherwise demonstrate to theIC’ssatisfaction that theLicensee has taken, or can be expected to take within a reasonable time, effective steps to achieve thePractical Applicationof theLicensed Productsor theLicensed Processes;

(b) has not achieved theBenchmarks as may be modified under Paragraph 9.2;

(c) has willfully made a false statement of, or willfully omitted a material fact in the license application or in any report required by thisAgreement;

(d) has committed a material breach of a covenant or agreement contained in thisAgreement;

(e) is not keeping theLicensed Products or theLicensed Processes reasonably available to the public after commercial use commences;

(f) cannot reasonably satisfy unmet health and safety needs; or

(g) cannot reasonably justify a failure to comply with the domestic production requirement of Paragraph 5.2 unless waived.

13.6 In making the determination referenced in Paragraph 13.5, theICshall take into account the normal course of such commercial development programs conducted with sound and reasonable business practices and judgment and the annual reports submitted by theLicensee under Paragraph 9.2. Prior to invoking termination or modification of thisAgreement under Paragraph 13.5, theIC shall give written notice to theLicensee providing theLicensee specific notice of, and a ninety (90) day opportunity to respond to, theIC’s concerns as to the items referenced in13.5(a)-13.5(g). If theLicensee fails to alleviate theIC’s concerns as to the items referenced in13.5(a)-13.5(g) or fails to initiate corrective action to theIC’s satisfaction, theIC may terminate thisAgreement.

A-429-2017

CONFIDENTIAL

NIH Patent License Agreement-Exclusive

Model 10-2015 Page 15 of 36 [Final] [Forte Biosciences]

[***] Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

13.7 When the public health and safety so require, and after written notice to theLicensee providing theLicensee a sixty (60) day opportunity to respond, theIC shall have the right to require theLicensee to grant sublicenses to responsible applicants, on reasonable terms, in anyLicensed Fields of Use under theLicensed Patent Rights, unless theLicensee can reasonably demonstrate that the granting of the sublicense would not materially increase the availability to the public of the subject matter of theLicensed Patent Rights. TheICshall not require the granting of a sublicense unless the responsible applicant has first negotiated in good faith with theLicensee.

13.8 TheICreserves the right according to35 U.S.C.§209(d)(3) to terminate or modify thisAgreement if it is determined that this action is necessary to meet the requirements for public use specified by federal regulations issued after the date of the license and these requirements are not reasonably satisfied by theLicensee.

13.9 Within thirty (30) days of receipt of written notice of theIC’s unilateral decision to modify or terminate thisAgreement,theLicenseemay, consistent with the provisions of37 C.F.R.§404.11,appeal the decision by written submission to the designatedICofficial or designee. The decision of the designatedICofficial or designee shall be the final agency decision. TheLicensee may thereafter exercise any and all administrative or judicial remedies that may be accessible.

13.10 Within ninety (90) days of expiration or termination of thisAgreement under this Article 13, a final report shall be submitted by theLicensee. Any royalty payments, including those incurred but not yet paid (such as the full minimum annual royalty), and those related to patent expenses, due to theIC shall become immediately due and payable upon termination or expiration. If terminated under this Article 13, sublicensees may elect to convert their sublicenses to direct licenses with theICpursuant to Paragraph 4.3. Unless otherwise specifically provided for under thisAgreement,upon termination or expiration of this Agreement,theLicenseeshall return allLicensed Productsor othermaterials included within the Licensed Patent Rightsto theICor provide theICwith certification of the destruction thereof. TheLicensee may not be granted additionalIClicenses if the final reporting requirement is not fulfilled.

14. GENERAL PROVISIONS

14.1 Neither party may waive or release any of its rights or interests in thisAgreementexcept in writing. The failure of theGovernmentto assert a right hereunder or to insist upon compliance with any term or condition of thisAgreement shall not constitute a waiver of that right by theGovernmentor excuse a similar subsequent failure to perform any of these terms or conditions by theLicensee.

14.2 ThisAgreement constitutes the entire agreement between the parties relating to the subject matter of theLicensed Patent Rights,theLicensed Productsand theLicensed Processes,and all priornegotiations, representations, agreements, and understandings are merged into, extinguished by, and completely expressed by thisAgreement.

A-429-2017

CONFIDENTIAL

NIH Patent License Agreement-Exclusive

Model 10-2015 Page 16 of 36 [Final] [Forte Biosciences]

[***] Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

14.3 The provisions of thisAgreement are severable, and in the event that any provision of thisAgreement shall be determined to be invalid or unenforceable under any controlling body of law, this determination shall not in any way affect the validity or enforceability of the remaining provisions of thisAgreement.

14.4 If either party desires a modification to thisAgreement,the parties shall, upon reasonable notice of the proposed modification by the party desiring the change, confer in good faith to determine the desirability of the modification. No modification shall be effective until a written amendment is signed by the signatories to thisAgreementor their designees.

14.5 The construction, validity, performance, and effect of thisAgreement shall be governed by Federal law as applied by the Federal courts in the District of Columbia.

14.6 AllAgreement notices required or permitted by thisAgreementshall be given by prepaid. first class, registered or certified mail or by an express/overnight delivery service provided by a commercial carrier, properly addressed to the other party at the address designated on the following Signature Page, or to another address as may be designated in writing by the other party.Agreement notices shall be considered timely if the notices arc received on or before the established deadline date or sent on or before the deadline date as verifiable by U.S. Postal Service postmark or dated receipt from a commercial carrier. Parties should request a legibly dated U.S. Postal Service postmark or obtain a dated receipt from a commercial carrier or the U.S. Postal Service. Private metered postmarks shall not be acceptable as proof of timely mailing.

14.7 ThisAgreementshall not be assigned or otherwise transferred (including any transfer by legal process or by operation of law, and any transfer in bankruptcy or insolvency, or in any other compulsory procedure or order of court) except to theLicensee’s Affiliate(s) without the prior Written consent of theIC. The parties agree that the identity of the parties is material to the formation of thisAgreementand that the obligations under thisAgreement are nondelegable. In the event that the IC approves a proposed assignment, the Licensee shall pay theIC as an additional royalty, [***] percent ([***]%) of theFair Valueof any consideration received for any assignment of thisAgreementwithin sixty(60) days of the assignment.

14.8 TheLicenseeagrees in its use of anyIC-supplied materials to comply with all applicable statutes, regulations, and guidelines, includingNIHandHHSregulations and guidelines. TheLicenseeagrees not to use the materials for research involving human subjects or clinical trials in the United States without complying with21 C.E.R. Part 50 and45 C.F.R. Part 46. TheLicensee agrees not to use the materials for research involving human subjects or clinical trials outside of the United States without notifying theIC, in \wiling, of the research or trials and complying with the applicable regulations of the appropriate national control authorities. Written notification to theIC of research involving human subjects or clinical trials outside of the United States shall he given no later than sixty (60) clays prior to commencement of the research or trials.

A-429-2017

CONFIDENTIAL

NIH Patent License Agreement-Exclusive

Model 10-2015 Page 17 of 36 [Final] [Forte Biosciences]

[***] Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

14.9 TheLicensee acknowledges that it is subject to and agrees to abide by the United States laws and regulations (including theExport Administration Act of 1979 andArms Export Control Act)controlling the export of technical data, computer software, laboratory prototypes, biological material, and other commodities. The transfer of these items may require a license from the appropriate agency of the U.S.Governmentor written assurances by theLicensee that it shall not export these items to certain foreign countries without prior approval of this agency. TheIC neither represents that a license is or is not required or that, if required, it shall be issued.

14.10 TheLicensee agrees to mark theLicensed Products or their packaging sold in the United States with all applicable U.S. patent numbers and similarly to indicate “Patent Pending” status. All theLicensed Products manufactured in, shipped to, or sold in other countries shall be marked in a manner to preserve theIC’s patent rights in those countries.

14.11 By entering into thisAgreement, theIC does not directly or indirectly endorse any product or service provided, or to be provided, by theLicensee whether directly or indirectly related to thisAgreement. TheLicensee shall not state or imply that thisAgreement is an endorsement by theGovernment, theIC, any otherGovernment organizational unit, or anyGovernment employee. Additionally, theLicensee shall not use the names of theIC, theFDA or theHHSor theGovernment or their employees in any advertising, promotional, or sales literature without the prior written approval of theIC.

14.12 The parties agree to attempt to settle amicably any controversy or claim arising under thisAgreementor a breach of thisAgreement,except for appeals of modifications or termination decisions provided for in Article 13. TheLicensee agrees first to appeal any unsettled claims or controversies to the designated IC official, or designee, whose decision shall be considered the final agency decision. Thereafter, theLicensee may exercise any administrative or judicial remedies that may be available.

14.13 Nothing relating to the grant of a license, nor the grant itself, shall be construed to confer upon any person any immunity from or defenses under the antitrust laws or from a charge of patent misuse, and the acquisition and use of rights pursuant to37 C.F.R. Part 404 shall not be immunized from the operation of state or Federal law by reason of the source of the grant.

14.14 Any formal recordation of thisAgreementrequired bythe laws of anyLicensed Territoryas a prerequisite to enforceability of theAgreement in the courts of any foreign jurisdiction or for other reasons shall be carried out by theLicenseeat its expense, and appropriately verified proof of recordation shall be promptly furnished to theIC.

14.15 Paragraphs 4.3, 8.1,9.5-9.8,12.1-12.5, 13.9, 13.10, 14.12 and 14.15 of thisAgreement shall survive termination of thisAgreement.

14.16 The terms and conditions of thisAgreement shall, at theIC’s sole option, be considered by theIC to be withdrawn from theLicensee’s consideration and the terms and conditions of thisAgreement,and theAgreementitself to be null and void, unless thisAgreementis executed by theLicenseeand a fully executed original is received by theIC within sixty (60) days from the date of theIC’s signature found at the Signature Page.

A-429-2017

CONFIDENTIAL

NIH Patent License Agreement-Exclusive

Model 10-2015 Page 18 of 36 [Final] [Forte Biosciences]

[***] Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

SIGNATURES BEGIN ON NEXT PAGE

A-429-2017

CONFIDENTIAL

NIH Patent License Agreement-Exclusive

Model 10-2015 Page 19 of 36 [Final] [Forte Biosciences]

[***] Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

NIH PATENT LICENSE AGREEMENT —EXCLUSIVE

SIGNATURE PAGE

For theIC:

/s/ Michael Mowatt	12/5/17
Michael Mowatt, Ph.D	Date
Director, Technology Transfer and Intellectual Property Office, NIAID

Mailing Address orE-mail Address forAgreementnotices and reports:

License Compliance and Administration

Monitoring & Enforcement

Office of Technology Transfer

National Institutes of Health

6011 Executive Boulevard, Suite 325

Rockville, Maryland 20852-3804 U.S.A.

E-mail: [***]

For theLicensee(Upon, information and belief, the undersigned expressly certifies or affirms that the contents of any statements of theLicenseemade or referred to in this document are truthful and accurate.):

By:

/s/ Paul Wagner	12/10/17
Signature of Authorized Official	Date
Name: Paul Wagner
Title: Member

I. Official and Mailing Address forAgreementnotices:

Paul Wagner, Ph.D.

Member

Mailing Address:
[***]
Email Address:	[***]
Phone:	[***]
Fax:	[***]

A-429-2017

CONFIDENTIAL

NIH Patent License Agreement-Exclusive

Model 10-2015 Page 20 of 36 [Final] [Forte Biosciences]

[***] Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

II. Official and Mailing Address for Financial notices (the Licensee’s contact person for royalty payments)

Paul Wagner

Member

Address:
[***]
Email Address:	[***]
Phone:	[***]
Fax:	[***]

Any false or misleading statements made, presented, or submitted to theGovernment,including any relevant omissions, under thisAgreementand during the course of negotiation of thisAgreementare subject to all applicable civil and criminal statutes including Federal statutes31 U.S.C.§§3801-3812 (civil liability) and 18§1001 (criminal liability including fine(s) or imprisonment).

A-429-2017

CONFIDENTIAL

NIH Patent License Agreement-Exclusive

Model 10-2015 Page 21 of 36 [Final] [Forte Biosciences]

[***] Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

APPENDIX A — PATENT(S) OR PATENT APPLICATION(S)

Patent(s) or Patent Application(s):

I.    US Provisional Application 62/324,762 [MS Ref#E-099-2016/0-US-01]

II.    PCT Patent Application PCT/US2017/028133 [HHS Ref#E-099-2016/0-PCT-02]

A-429-2017

CONFIDENTIAL

NIH Patent License Agreement-Exclusive

Model 10-2015 Page 22 of 36 [Final] [Forte Biosciences]

[***] Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

APPENDIX B — LICENSED FIELDS OF USE AND TERRITORY

I. Licensed Fields of Use:

Use of pharmaceutical and biological compositions comprising Gram-negative bacteria for the topical treatment of dermatological diseases and dermatological conditions.

II. Licensed Territory:Worldwide

A-429-2017

CONFIDENTIAL

NIH Patent License Agreement-Exclusive

Model 10-2015 Page 23 of 36 [Final] [Forte Biosciences]

[***] Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

APPENDIX C — ROYALTIES

Royalties:

I. TheLicenseeagrees to pay to theIC a noncreditable, nonrefundable license issue royalty in the amount of [***] dollars ($[***]) within sixty (60) days from the effective date of thisAgreement.

II. TheLicenseeagrees to pay to the IC a nonrefundable minimum annual royalty in the amount of twenty thousand dollars ($20,000) as follows:

(a) The first minimum annual royalty is due within sixty (60) days of the effective date of this Agreement and may be prorated according to the fraction of the calendar year remaining between the effective date of this Agreement and the next subsequent January 1; and

(b) Subsequent minimum annual royalty payments are due and payable on January I of each calendar year and may be credited against any earned royalties due for sales made in that year.

III. TheLicensee agrees to pay theIC earned royalties of [***] percent ([***]%) onNet Sales by or on behalf of theLicensee and its sublicensees.

IV. TheLicensee agrees to pay theICBenchmarkroyalties within sixty (60) days of achieving eachBenchmark:

(a) [***] dollars ($[***]) upon completion of patient enrollment of a Phase III clinical trial in theLicensed Field ofUse

(b) [***] dollars ($[***]) upon the completion of a Phase HI clinical trial demonstrating statistical significant efficacy benefit ofLicenced Product

(c) [***] dollars ($[***]) upon first FDA approval ofLicensed Product.An additional [***] dollars ($[***]) shall be paid for each additional FDA approvedLicensed Product

(d) [***] dollars ($[***]) upon firstnon-U.S. territory approval ofLicensed Product.An additional [***] dollars ($[***]) shall be paid for each additionalnon-U.S. territory approval ofLicensed Product

(e) [***] dollars ($[***]) - First $100 million of annual Net Sales

(f) [***] dollars ($[***]) - First $500 million of annual Net Sales

(g) [***] dollars ($[***]) - First $1,000 million of annual Net Sales

V. TheLicensee agrees to pay theIC additional sublicensing royalties of [***] percent ([***]%) on theFair Valueof any consideration received for each sublicense in accordance with Article 4 of thisAgreement within sixty (60) days of the execution of each sublicense.

A-429-2017

CONFIDENTIAL

NIH Patent License Agreement-Exclusive

Model 10-2015 Page 24 of 36 [Final] [Forte Biosciences]

[***] Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

APPENDIX D — BENCHMARKS AND PERFORMANCE

TheLicensee agrees to the followingBenchmarks for its performance under thisAgreement and, within thirty (30) days of achieving aBenchmark, shall notify theIC that theBenchmark has been achieved.

[***]

A-429-2017

CONFIDENTIAL

NIH Patent License Agreement-Exclusive

Model 10-2015 Page 25 of 36 [Final] [Forte Biosciences]

[***] Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

APPENDIX E — COMMERCIAL DEVELOPMENT PLAN

Introduction and Overview - Atopic Dermatitis

Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by pruritus (itching) and xerosis (dry skin). AD pruritis can be severe, leading to changes in the skin, including thickening of the skin (lichenification), breakdown of the skin barrier and scarring. Xerosis in atopic dermatitis results from the disruption of the epidermal integrity and further dysfunction of the skin barrier. Atopic dermatitis lesions present most commonly on the scalp, face and extremities and can vary depending on the degree of inflammation and secondary infection. Both environmental and genetic factors appear to contribute to the pathogenesis of atopic dermatitis with hyper-reactive basophils and mast cells resulting in increased histamine and leukotriene production and elevated serum IgE. Bacterial infections are also common in atopic dermatitis patients and the significant majority of AD patients are colonized with toxin producing S. aureus. S. auerus toxins and superantigen presentation are believed to contribute to the pathogenesis of AD.

According to the American Academy of Dermatology, worldwide, between 10% and 20% of children suffer from atopic dermatitis (AD) and approximately 1% to 3% of adults experience AD. Atopic dermatitis most commonly occurs before the 5th birthday and approximately 50% of children with AD will experience a recurrence in adulthood.

Current Treatment Algorithm

The treatment of atopic dermatitis focuses on addressing the associated pruritus, xerosis, inflammation and infection. For mild breakthrough AD, low to moderate strength topical corticosteroids are used along with antihistimines as needed to address itching. For mild to moderate AD, increased intensity topical corticosteroids are employed along with regular use of antihistimines. If symptoms do not improve, phototherapy and systemic therapies can be administered. According to the AAD guidelines for atopic dermatitis, systemic therapies can include cyclosporine, methotrexate, mycophenolate mofetil, and azathioprine as well as leukotriene inhibitors and oral calcineurin inhibitors. The management of AD with systemic corticosteroids is recommended to be avoided because of adverse side effects and unfavorable risk-benefit of systemic corticosteroids for atopic dermatitis. Treatment of S. aureus infections, which contributes to the AD pathogenesis, can be treated with antibiotics and bleach baths.

A-429-2017

CONFIDENTIAL

NIH Patent License Agreement-Exclusive

Model 10-2015 Page 26 of 36 [Final] [Forte Biosciences]

[***] Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

More recently, Regeneron and Sanofi’s Dupixent (dupilumab), an antibody targeting theIL-4 receptor alpha, was approved by FDA for the treatment of adult patients with moderate to severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupixent can be used with or without topical corticosteroids.

DUPIXENT efficacy result

	Trial 1						Trial 2						Trial 3
	DUPIXENT 300 Q2w			Placebo			DUPIXENT 300 Q2w			Placebo			DUPIXENT 300 Q2w + TCS			Placebo + TCS
Number of subjects randomized (FAS)a		224			224			233			236			106			315
IGA O OR 1D,C		38	%		10	%		36	%		9	%		39	%		12	%
EASI-75C		51	%		15	%		44	%		12	%		69	%		23	%
EASI-90C		36	%		8	%		30	%		7	%		40	%		11	%
Number of subjects with baseline Peak Pruritus NAS score³4		213			212			225			221			102			299
Peak Pruritus NRS (³4-point improvement)C		41	%		12	%		36	%		10	%		59	%		20	%

^a Full Analysis Sol (FAS) includes all subjects randomized

^b  Responder was defined as a subject with IGA 0 or I (“clear” or almost clear”) with a reduction of³ on a0-4 IGA scale

^c  Subjects who received rescue treatment or with missing data were considered asnon-responders

DUPIXENT adverse reaction profile

	DUPIXENT Monotherapy						DUPIXENT + TCSb
Adverse Reaction	DUPIXENT 300 mg Q2W N=529 n (%)			Placebo N=517 n (%)			DUPIXENT 300 mg Q2w + TCS N=110 n (%)			Placebo + TCS N=315 n=(%)
Injection site reactions		51	(10)		28	(5)		11	(10)		18	(6)

A-429-2017

CONFIDENTIAL

NIH Patent License Agreement-Exclusive

Model 10-2015 Page 27 of 36 [Final] [Forte Biosciences]

[***] Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

ConjunctivitisD	51 (10)	12 (2)	10 (9)	15 (5)
Blepharitis	2 (<1)	1 (<1)	5 (5)	15 (5)
Oral herpes	20 (4)	8 (2)	3 (3)	5 (2)
Keratitis	1 (<1)	0	4 (4)	0
Eye Pruritus	3 (1)	1 (<1)	2 (2)	2 (1)
Other herpes simplex virus infection	10 (2)	6 (1)	1 (1)	1 (<1)
Dry eye	1 (<1)	0	2 (2)	1 (<1)

^a pooled analysis of Trials 1, 2, and 4

^b  analysis of Trial 3 where subjects were on background TCS therapy

^c  DUPIXENT 600 mg at Week O, followed by 300 mg every two weeks

^d Conjunctivitis cluster includes conjunctivitis, allergic conjunctivitis, bacterial conjunctivitis, viral conjunctivitis, giant papillary conjunctivitis, eye irritation and eye inflammation.

^e Keratitis cluster includes Keratitis, ulcerative keratitis, allergic keratitis, atopic keratoconjunctivitis and opthalmic herpes simplex.

^f Other herpes simplex virus infection cluster includes herpes simplex, genital herpes, herpes simplex oxits eczema, and herpes virus infection, but excludes eczema herpeticum.

A-429-2017

CONFIDENTIAL

NIH Patent License Agreement-Exclusive

Model 10-2015 Page 28 of 36 [Final] [Forte Biosciences]

[***] Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

Microbiome transplantation for treatment of patients with atopic dermatitis

Gram-negative microbiota differ between healthy controls and patients with AD, Myles et al. identified that the predominant gram-negative species identified on healthy volunteers as Roseomonas mucosa. Overgrowth and infection with S. aureus are both contributors totheimmune imbalance and poor barrier function in AD. Treatment with antibiotics can reduce S. aureus burdens and improve symptoms but does not normalize the underlying pathology. Myles and Datta found that supernatants from healthy volunteer, gram negative culturable bacteria inhibited S. aureus by nearly 50% versus the media control and that select strains of the gram-negative bacteria R. mucosa from healthy controls transplanted onto the skin influenced S. aureus growth, transepidermal water loss associated with AD and influenced certain parameters of innate immune activation. The authors concluded that a live biotherapeutic approach may hold promise for treatment of patients with atopic dermatitis and have initiated clinical studies testing the safety and efficacy of topically administered R. mucosa for the treatment of AD.

Forte Biosciences

[***]

Process Development and Manufacturing Detailed Overview

Process development, formulation, manufacturing and fill/finish of the drug product will conducted in accordance with the USP and FDA guidance.

In brief, process development of the drug product will include selection and testing to determine optimal vialing format, formulation development of the spray nozzle applicator and development of validation of the product quality and performance parameters

Testing will be conducted to assess bacterial suspension in solution in comparison to lyophilization, required reconstitution parameters, stability and bacterial proliferation parameters, cell viability/stability, spray dispersion and consistency of bacterial delivery, aerosolizing parameter definition and testing and contaminant microorganism characterization.

Background on manufacturing and formulation guidance for topical drug products

FDA has issued guidance for the current good manufacturing practice (CGMP) of topical drug product production.

The key focus for the CGMP of topical drug products focuses on the active ingredient uniformity, physical characteristics and chemical and microbial purity. FDA examination of manufacturing and control data and correspondence is to be complete early in the process and the specific and complete control data contained in the application is to be compared to the clinical batches and the production validation batches. In the case of the live bacterial topical biotherapeutic assurance of uniform potency and dispersion is required.Inthis case both the bacterial viability/stability in the final drug product containment will need to be assessed. If the final drug product is in solution, the parameters of the reproducibility of the bacterial delivery (spray coating) are to be defined. Production temperature and sterility is akeyto confirm that no objectionable microorganism

A-429-2017

CONFIDENTIAL

NIH Patent License Agreement-Exclusive

Model 10-2015 Page 29 of 36 [Final] [Forte Biosciences]

[***] Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

are present. SOPs for cleaning validation will be established to preclude contamination of current and future batches. FDA emphasizes that it is therefore vital that manufacturers assess the health hazard of all organisms isolated from the drug product. Undesirable microbaterial growth factors which influence microbial growth include flow rates, temperature, surface area of resin beds and the microbial quality of the feed water.

A-429-2017

CONFIDENTIAL

NIH Patent License Agreement-Exclusive

Model 10-2015 Page 30 of 36 [Final] [Forte Biosciences]

[***] Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

Microbiological Specifications and Test Methods for Topical Drug Products

During inspections it is important to audit the microbiological specifications and microbial test methods used for each topical product to assure that they are consistent with any described in the relevant application. FDA has commented that it is often helpful for the inspection to include an FDA microbiologist.

Generally, product specifications should cover the total number of organisms permitted, as well as specific organisms that must not be present. These specifications must be based on use of specified sampling and analytical procedures. Where appropriate, the specifications should describe action levels where additional sampling and/or speciation of organisms is necessary.

Manufacturers must demonstrate that the test methods and specifications are appropriate for their intended purpose. Where possible, methods should be utilized that isolate and identify organisms that may present a hazard to the user under the intended use.

In assessing the significance of microbial contamination of a topical product, both the identification of the isolated organisms and the number of organisms found are significant. For example, the presence of a high number of organisms may indicate that the manufacturing process, component quality, and/or container integrity may be deficient. Although high numbers ofnon-pathogenic organisms may not pose a health hazard, they may affect product efficacy and/or physical/chemical stability. Inconsistent batch to batch microbial levels may indicate some process or control failure in the batch. The batch release evaluation should extend to both organism identification and numbers and, if limits are exceeded, there should be an investigation into the cause.

In addition, “The Topical and Transdermal Drug Products” monograph from the topical/transdermal ad hoc advisory panel for the USP performance tests of topical and transdermal dosage forms defines the parameters for drug device combinations that have local action at or on the surface of the skin.

The USP monograph defines two categories of tests: product quality tests and product performance tests, that are to be performed with topically administered drug products to provide assurances ofbatch-to-batch quality, reproducibility, reliability, and performance. Product quality tests are performed to assess attributes such as assay, identification, content uniformity, pH, microbial limits, and minimum fill and are part of the compendial monograph. Product performance tests are conducted to assess drug release from the finished dosage form.

[***]

A-429-2017

CONFIDENTIAL

NIH Patent License Agreement-Exclusive

Model 10-2015 Page 31 of 36 [Final] [Forte Biosciences]

[***] Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

Using the recently approved Dupixent systemic therapy as a benchmark for clinical development in atopic dermatitis, approval may require 3 clinical trials in approximately 1,300 patients examining therapy vs placebo and therapy on top of topical corticosteroids. Endpoints may include investigator global assessment of 0 or 1 (clear or almost clear) and greater than 2 point improvement from baseline,EASI-75 (75% or greater improvement from baseline of eczema and severity index) ,EASI-90 (90% improvement from baseline of eczema and severity index) and a greater than 4 point improvement in the peak pruritis scoring.

	Trial 1						Trial 2						Trial 3
	DUPIXENT 300 mg Q2W			Placebo			DUPIXENT 300 mg Q2W			Placebo			DUPIXENT 300 mg Q2W + TCS			Placebo + TCS
Number of subjects randomized (FAS)		224			224			233			236			106			315
IGA 0 or 1b,c		38	%		10	%		36	%		9	%		39	%		12	%
EASI-75c		51	%		15	%		44	%		12	%		69	%		23	%
EASI-90c		36	%		8	%		30	%		7	%		40	%		11	%
Number of subjects with baseline Peak Pruitus NRS score³4		213			212			225			221			102			299
Peak Pruitus NRS (³4-point improvement)c		41	%		12	%		36	%		10	%		59	%		20	%

^a  Full Analysis Set (FAS) includes all subjects randomized.

^b  Responder was defined as a subject with IGA 0 or 1 (“clear” or “ almost clear”) with a reduction of³2 points on a0-4 IGA scale.

^c  Subjects who received rescue treatment or with missing data were considered asnon-responders.

A-429-2017

CONFIDENTIAL

NIH Patent License Agreement-Exclusive

Model 10-2015 Page 32 of 36 [Final] [Forte Biosciences]

[***] Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

Commercialization

According to the National Eczema Association, 31.6 million people in the US suffer with atopic dermatitis, (17.8 million with moderate to severe atopic dermatitis). Theprevalence of childhood eczema/atopic dermatitis in the US is 10.7% overall. Approximately one out of every three children with eczema/atopic dermatitis has moderate to severe disease. A recent study found that the prevalence of eczema in adults could be as high as 10.2%. Three percent of US adults have moderate to severe eczema/atopic dermatitis requiring systemic therapy. These numbers are much higher than for psoriasis, a disease that now has many good-targeted treatments for moderate to severe patients. There are still very large unmet needs for the treatment of patients with eczema / atopic dermatitis that could be address with a topical live biotherapeutic approach.

The current pricing for the recently approved systemic antibody therapy Dupixent is $37,000 per year.

The final pricing and market opportunity for the topical live biotherapeutic will be a function of the detailed efficacy and safety data obtained from the phase 3 trial; however, we believe that a topical live biotherapeutic could offer meaningful benefit to atopic dermatitis patients at a fraction of the cost and with lower risk (topical vs systemic).

[***]

A-429-2017

CONFIDENTIAL

NIH Patent License Agreement-Exclusive

Model 10-2015 Page 33 of 36 [Final] [Forte Biosciences]

[***] Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

APPENDIX F - EXAMPLE ROYALTY REPORT

Required royalty report information includes:

• License reference number(L-XXX-200X/0)

• Reporting period

• Catalog number and units sold of each Licensed Product (domestic and foreign)

• Gross Sales per catalog number per country

• Total Gross Sales

• Itemized deductions from Gross Sales

• Total Net Sales

• Earned Royalty Rate and associated calculations

• Gross Earned Royalty

• Adjustments for Minimum Annual Royalty (MAR) and other creditable payments made

• Net Earned Royalty due

Example

Catalog Number	Product Name	Country	Units Sold	Gross Sales (US$)
1	A	US	250	62,500
1	A	UK	32	16,500
1	A	France	25	15,625
2	B	US	0	0
3	C	US	57	57,125
4	D	US	12	1,500
		Total Gross Sales		153,250
		Less Deductions:
			Freight	3,000
			Returns	7,000
			Total Net Sales	143,250
			Royalty Rate	8%
			Royalty Due	11,460
		Less Creditable Payments		10,000
			Net Royalty Due	1,460

A-429-2017

CONFIDENTIAL

NIH Patent License Agreement-Exclusive

Model 10-2015 Page 34 of 36 [Final] [Forte Biosciences]

[***] Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

APPENDIX G — ROYALTY PAYMENT OPTIONS

The License Number MUST appear on payments, reports and correspondence.

Credit and Debit Card Payments

Credit and debit card payments can be submitted for amounts up to $29,999. Submit your payment through the U.S. Treasury web site located at:https://www.nav,govinubliciform/start/28680443.

Automated Clearing House (ACH) for payments through U.S. banks only

TheIC encourages its licensees to submit electronic funds transfer payments through the Automated Clearing House (ACH). Submit your ACH payment through the U.S. Treasury web site located at:huns://www.pay.mov/public/liirm/start/28680443. Please note that the IC “only” accepts ACH payments through this U.S. Treasury web site.

Electronic Funds Wire Transfers

The following account information is provided for wire payments. In order to process payment via Electronic Funds Wire Transfer sender MUST supply the following information within the transmission:

Drawn on aU.S. bank account via FEDWIRE should be sent directly to the following account:

[***]

Drawn on aforeign bank account should be sent directly to the following account. Payment must be sent inU.S. Dollars (USD) using the following instructions:

[***]

A-429-2017

CONFIDENTIAL

NIH Patent License Agreement-Exclusive

Model 10-2015 Page 38 of 36 [Final] [Forte Biosciences]

[***] Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

Checks

All checks should be made payable to “NIH Patent Licensing”

Checks drawn on aU.S. bank account and sent by US Postal Service should be sent directly to the following address:

National Institutes of Health

P.O. Box 979071

St. Louis, MO 63197-9000

Checks drawn on a U.S. bank account and sent byovernight or courier should be sent to the following address:

US Bank

Government LockboxSL-MO-C2GL

1005 Convention Plaza

St. Louis, MO 63101

Phone:314-418-4087

Checks drawn on aforeign bank account should be sent directly to the following address:

National Institutes of Health

Office of Technology Transfer

License Compliance and Administration

Royalty Administration

6011 Executive Boulevard

Suite 325, MSC 7660

Rockville, Maryland 20852

A-429-2017

CONFIDENTIAL

NIH Patent License Agreement-Exclusive

Model 10-2015 Page 39 of 36 [Final] [Forte Biosciences]

[***] Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.